Announcement • Jun 04
Coloplast Announces FDA Approval of Titan Prime Inflatable Penile Prosthesis Coloplast announced FDA approval of Titan Prime, an inflatable penile prosthesis (IPP) that represents the company’s next-generation device and will be available in the U.S. in late 2026. Around 30 million men in the US experience ongoing difficulty in getting or keeping an erection firm enough for sexual activity. As an alternative to medication, some benefit from long-term treatment options such as an inflatable penile prosthesis, which is delivered through a single outpatient procedure. Inflatable Penile Prosthesis Titan Prime IPP is designed to emulate the appearance and performance of a natural erection, supporting device performance for patients, surgeons, and partners. Built with proprietary Bioflex – a polymer engineered for greater strength and durability than silicone – Titan Prime IPP delivers greater material strength than leading silicone competitors and withstands higher pressures to reinforce reliability. Titan Prime IPP preserves the rigidity and girth surgeons trust from Titan IPP today, while providing improved flaccid flexibility for comfort and concealability. The result is consistent, predictable outcomes across diverse male anatomies. Titan Prime is now FDA-approved and will be available through a phased launch to urologists and health care systems in the United States beginning in late 2026. Titan Prime IPP is approved for use in the United States by the FDA. Coloplast is pursuing regulatory approvals in other countries, where the product is not yet available. Board Change • May 20
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 6 highly experienced directors. Independent Director Niels Christiansen was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • May 13
Coloplast A/S Announces Interim Dividend for the First Half Ended March 31, 2026 Coloplast A/S announced that it will pay a interim dividend of DKK 5.00 per share, for a total dividend pay-out of DKK 1,127 million for the first half ended March 31, 2026. Announcement • Mar 07
Coloplast A/S Announces President Changes Coloplast A/S's board of directors announced the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-dollar business with more than 7,000 employees working across three business units: Surgery, Orthopedics, and Cardiovascular & Specialty Solutions. Earlier in his career, he led the Ethicon Wound Closure & Healing team as Worldwide President, and prior to that, he served as Executive Vice President, Commercial, at Mölnlycke. Gavin Wood currently serves as Vice Chair of the MedTech Europe trade association. He holds a Bachelor of Arts degree in Law from Carleton University, Canada and an MBA from Queen’s University, Canada. He is Canadian by birth, currently lives in Switzerland, and he will be relocating to Denmark. Lars Rasmussen will continue to lead Coloplast as interim CEO until the end of April. Announcement • Mar 06
Coloplast A/S Announces CEO Changes Coloplast A/S's board of directors announced the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-dollar business with more than 7,000 employees working across three business units: Surgery, Orthopedics, and Cardiovascular & Specialty Solutions. Earlier in his career, he led the Ethicon Wound Closure & Healing team as Worldwide President, and prior to that, he served as Executive Vice President, Commercial, at Mölnlycke. Gavin Wood currently serves as Vice Chair of the MedTech Europe trade association. He holds a Bachelor of Arts degree in Law from Carleton University, Canada and an MBA from Queen’s University, Canada. He is Canadian by birth, currently lives in Switzerland, and he will be relocating to Denmark. Lars Rasmussen will continue to lead Coloplast as interim CEO until the end of April. Announcement • Feb 06
Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2025-2026 Coloplast A/S provided earnings guidance for the fiscal year 2025-2026. For the year, the company expects around 7% EBIT growth in constant currencies. Board Change • Dec 30
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 4 highly experienced directors. Independent Director Niels Christiansen was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Dec 19
Coloplast A/S Announces Executive Changes Coloplast A/S announced changes to its Executive Leadership Team, affecting the Interventional Urology business and the global People & Culture function. Executive Vice President of People & Culture, Dorthe Rønnau, has decided to leave Coloplast to pursue the next chapter in her career. She has spent close to three decades in different roles across the Coloplast Group, including Global Operations, Atos, and People & Culture, and in her role in the Executive Leadership Team. An external search is currently on-going to identify a new leader of the global People & Culture function. Dorthe Rønnau will have her last day at Coloplast at the end of February 2026, where Mads Mikkelsen, Vice President, People & Culture, Chronic Care Commercial, will take over the interim leadership of the global People & Culture organisation until a permanent successor has been identified. After more than a decade in Coloplast and more than three decades in the global life science industry, Tommy Johns, Executive Vice President of Interventional Urology, will retire early next year. Tommy Johns has been instrumental in identifying his successor, ensuring a period of overlap between Tommy and his successor to ensure a thorough handover prior to Tommy’s final day with Coloplast early next year. Kevin Hardage will step into the role of Executive Vice President of Interventional Urology. He joins Coloplast on February 9, 2026. Kevin brings extensive experience from the global MedTech industry, including senior leadership experience from Teleflex in the urology space. Announcement • Oct 09
Coloplast A/S Announces Interim CEO Lars Rasmussen Will Step Down from the Board At the Upcoming Annual General Meeting on December 4, 2025 Coloplast interim CEO Lars Rasmussen has informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, 2025. Lars Rasmussen will, as announced earlier this year, continue in the role as interim CEO until a new CEO of Coloplast is in place. Jette Nygaard-Andersen will continue in the role of interim Chair and, together with the Board of Directors, lead Coloplast in the coming period, as the company enters into its next strategic period of long-term, sustainable growth and value creation. Jette Nygaard-Andersen has been a member of the Board since December 2015 and interim Chair since May 5, 2025. The Board of Directors are unanimously supportive of the announced changes. The search for Coloplast’s new CEO is progressing according to plan, and an announcement will follow once a decision has been made. Announcement • Oct 01
Coloplast A/S, Annual General Meeting, Dec 03, 2026 Coloplast A/S, Annual General Meeting, Dec 03, 2026. Board Change • Dec 30
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. Independent Director Annette Bruls was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Dec 05
An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B). An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B) on December 3, 2024.
For the period ending September 30, 2024, Coloplast's Skin Care business reported total revenue of DKK 400 million.
An undisclosed buyer completed the acquisition of Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B) on December 3, 2024. Announcement • Nov 15
Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy Coloplast A/S announced on 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD) policy regarding skin substitute grafts/cellular and tissue-based products for the treatment of Diabetic Foot Ulcers (DFUs) and venous leg ulcers (VLUs) in the Medicare population. The final LCD policy confirms the introduction of a technical qualification and a clinical efficacy qualification, proposed in a draft LCD policy2 earlier this year. The final decision also introduces two separate lists for covered products for DFUs and covered products for VLUs. In addition, the application limit has been expanded from 4 to 8 and the duration of treatment has been increased from 12 to 16 weeks in the final policy. The implementation date of the final policy is set to 12 February 2025. Based on the final evaluation, Kerecis is included on the final list of covered products for DFUs, however, Kerecis has not been included on the covered list for VLUs. Sales related to VLUs in the out-patient setting currently represent a low-single digit portion of the total Kerecis’ sales. Kerecis has an ongoing clinical study on VLUs and will attempt to get coverage for VLUs as soon as the study is completed. Declared Dividend • Nov 08
Final dividend of kr.17.00 announced Shareholders will receive a dividend of kr.17.00. Ex-date: 6th December 2024 Payment date: 10th December 2024 Dividend yield will be 14%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not adequately covered by earnings (98% earnings payout ratio) nor is it covered by cash flows (349% cash payout ratio). The dividend has increased by an average of 7.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 8.8% to bring the payout ratio under control. EPS is expected to grow by 46% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Announcement • Nov 06
Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025 Coloplast A/S announced that they will report nine months, 2025 results on Aug 19, 2025 Reported Earnings • Nov 05
Full year 2024 earnings released: EPS: kr.22.46 (vs kr.22.21 in FY 2023) Full year 2024 results: EPS: kr.22.46 (up from kr.22.21 in FY 2023). Revenue: kr.27.0b (up 10% from FY 2023). Net income: kr.5.05b (up 5.6% from FY 2023). Profit margin: 19% (in line with FY 2023). Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Announcement • Sep 27
Coloplast A/S, Annual General Meeting, Dec 04, 2025 Coloplast A/S, Annual General Meeting, Dec 04, 2025. Reported Earnings • Aug 21
Third quarter 2024 earnings released: EPS: kr.5.67 (vs kr.5.99 in 3Q 2023) Third quarter 2024 results: EPS: kr.5.67. Revenue: kr.6.89b (up 13% from 3Q 2023). Net income: kr.1.27b (flat on 3Q 2023). Profit margin: 19% (down from 21% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Announcement • Aug 20
Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24 Coloplast A/S re-affirmed earnings guidance for the fiscal year 2023/24. For the period, the company expects organic revenue growth to be around 8%. Reported growth in DKK is expected to be 10% to 11%. Declared Dividend • May 09
First half dividend of kr.5.00 announced Shareholders will receive a dividend of kr.5.00. Ex-date: 13th May 2024 Payment date: 15th May 2024 Dividend yield will be 6.3%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not adequately covered by earnings (94% earnings payout ratio) nor is it covered by cash flows (448% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 4.1% to bring the payout ratio under control. EPS is expected to grow by 43% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. New Risk • May 07
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 9.7% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.7% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Payout ratio: 94% Cash payout ratio: 448% Minor Risk Shareholders have been diluted in the past year (5.9% increase in shares outstanding). Reported Earnings • May 07
Second quarter 2024 earnings released: EPS: kr.5.57 (vs kr.5.44 in 2Q 2023) Second quarter 2024 results: EPS: kr.5.57 (up from kr.5.44 in 2Q 2023). Revenue: kr.6.59b (up 8.7% from 2Q 2023). Net income: kr.1.25b (up 8.4% from 2Q 2023). Profit margin: 19% (in line with 2Q 2023). Revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 11
First quarter 2024 earnings released First quarter 2024 results: Revenue: kr.6.61b (up 8.2% from 1Q 2023). Net income: kr.1.21b (up 7.5% from 1Q 2023). Profit margin: 18% (in line with 1Q 2023). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Announcement • Feb 01
Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US Coloplast A/S aims to expand its position within advanced wound care by introducing a new silicone foam that will benefit both healthcare professionals and patients. Changing demographics and an aging population are leading to a higher demand for healthcare services, putting significant strain on healthcare systems. In the US, chronic wounds are reported to affect 10.5 million patients annually1, while 2.5 million patients develop a pressure injury in acute care facilities each year2. Therefore, it is critical for healthcare providers to choose products that simplify their workflows and deliver the best possible care for their patients. Announcement • Dec 08
Coloplast A/S Approves the Distribution of Year-End Dividend Coloplast A/S approved the distribution of year-end dividend of DKK 16 per share of nominally DKK 1, at the AGM held on December 7, 2023. Buying Opportunity • Nov 10
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 16%. The fair value is estimated to be €117, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.4%. For the next 3 years, revenue is forecast to grow by 9.0% per annum. Earnings is also forecast to grow by 12% per annum over the same time period. Reported Earnings • Nov 10
Full year 2023 earnings released Full year 2023 results: Revenue: kr.24.5b (up 8.5% from FY 2022). Net income: kr.4.78b (up 1.6% from FY 2022). Profit margin: 20% (down from 21% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Recent Insider Transactions • Sep 03
Deputy Chairman recently bought €5.4m worth of stock On the 1st of September, Niels Louis-Hansen bought around 53k shares on-market at roughly €101 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Niels' only on-market trade for the last 12 months. Announcement • Sep 02
Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion on July 7, 2023. The total enterprise value for 100% ownership of Kerecis amounts to up to $1.3 billion, consisting of $1.2 billion upfront cash payment and an earnout potential of maximum $100 million dependent on financial performance in FY 2023/24. The transaction is expected to be financed through an equity capital raise of around DKK 9 billion ($1.3 billion). Following the expected acquisition, Kerecis will operate as a stand-alone business unit under its own identity and brand. Kerecis reported a revenue of DKK 510 million ($74.36 million) in FY 2021/22.
Closing of the transaction is subject to customary regulatory approvals and an acceptance threshold of at least 90%, and is anticipated in Q4 2022/23. Kerecis’ Board of Directors has recommended to the company’s minority shareholders to sell their shares in Kerecis to Coloplast. 77% of Kerecis’ shareholders have committed to sell their shares to Coloplast. The acquisition is expected to be margin dilutive short-term for Coloplast. The transaction is expected to be increasingly EPS accretive from FY 2026/27. Coloplast’s financial guidance for FY 2022/23 excluding transaction related costs is unchanged. Special items for FY 2022/23 are expected to increase by DKK 50 million due to transaction related costs (advisory fees).
Ulrik Falk, Morten Sløk and Niklas Mortensen of FIH Partners acted as financial advisors to Coloplast A/S. Jeppe Buskov, Morten Kofmann and Oliver Machholdt of Kromann Reumert acted as Lead Legal Advisor and PWC acted as financial advisor to Coloplast. Danske Bank will act as Sole Global Coordinator in connection with the equity capital raise and Joint Bookrunner together with Nordea. J.P. Morgan acted as exclusive financial advisor to Kerecis. Logos Legal Services advised Kerecis on Icelandic law matters. Mark P. Holloway, Michael C. Labriola, Ross Davies, Sarah Lane, Stephen R. Heifetz, Michael S. Casey, Anne E. Seymour, Beau Buffier, Kimberley Biagioli, Andrew Poling, Martin Luff, Matt Staples and Paul S. Gadiock of Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisor to Kerecis.
Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC on August 31, 2023. New Risk • Sep 01
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks High level of debt (314% net debt to equity). Shareholders have been diluted in the past year (5.8% increase in shares outstanding). Reported Earnings • Aug 18
Third quarter 2023 earnings released: EPS: kr.5.99 (vs kr.6.07 in 3Q 2022) Third quarter 2023 results: EPS: kr.5.99 (down from kr.6.07 in 3Q 2022). Revenue: kr.6.11b (up 4.4% from 3Q 2022). Net income: kr.1.27b (down 1.3% from 3Q 2022). Profit margin: 21% (down from 22% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Announcement • Aug 17
Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023 Coloplast A/S provided earnings guidance for the fiscal year 2022/2023. Organic revenue growth continues to be expected around 8%. Reported revenue growth is still expected at 8% to 9%. Announcement • Jul 08
Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion. Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion on July 7, 2023. The total enterprise value for 100% ownership of Kerecis amounts to up to $1.3 billion, consisting of $1.2 billion upfront cash payment and an earnout potential of maximum $100 million dependent on financial performance in FY 2023/24. The transaction is expected to be financed through an equity capital raise of around DKK 9 billion ($1.3 billion). Following the expected acquisition, Kerecis will operate as a stand-alone business unit under its own identity and brand. Kerecis reported a revenue of DKK 510 million ($74.36 million) in FY 2021/22. Closing of the transaction is subject to customary regulatory approvals and an acceptance threshold of at least 90%, and is anticipated in Q4 2022/23. Kerecis’ Board of Directors has recommended to the company’s minority shareholders to sell their shares in Kerecis to Coloplast. 77% of Kerecis’ shareholders have committed to sell their shares to Coloplast. The acquisition is expected to be margin dilutive short-term for Coloplast. The transaction is expected to be increasingly EPS accretive from FY 2026/27. Coloplast’s financial guidance for FY 2022/23 excluding transaction related costs is unchanged. Special items for FY 2022/23 are expected to increase by DKK 50 million due to transaction related costs (advisory fees).FIH Partners acted as transaction advisors, Kromann Reumert acted as Lead Legal Advisors, and PWC acted as financial advisors to Coloplast. Danske Bank will act as Sole Global Coordinator in connection with the equity capital raise and Joint Bookrunner together with Nordea. J.P. Morgan acted as exclusive financial advisor to Kerecis. Announcement • May 11
Coloplast A/S Provides Earnings Guidance for the Fiscal 2023 Coloplast A/S provided earnings guidance for the full fiscal year 2022/2023. For the period, the company reports organic revenue growth is now expected around 8% in constant exchange rates, from 7-8% previously. Reported growth in DKK is now expected to be 8-9%, from previously 9-10%, due to negative impact from currencies. Consequently, the reported EBIT margin is now expected in the 28-29% range, from previously 28-30%. Reported Earnings • Feb 05
First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022) First quarter 2023 results: EPS: kr.5.31 (down from kr.5.67 in 1Q 2022). Revenue: kr.6.11b (up 18% from 1Q 2022). Net income: kr.1.13b (down 6.6% from 1Q 2022). Profit margin: 19% (down from 23% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Announcement • Feb 04
Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections Coloplast launches male catheter designed to reduce the risk of urinary tract infections. The new intermittent catheter Luja addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole. Urinary tract infections represent a significant challenge for people who use intermittent catheters to empty their bladder. This includes people living with spinal cord injury, multiple sclerosis, or spina bifida. On average, intermittent catheter users have 2-3 urinary tract infections per year1-3, which can lead to serious health complications4, have a significant impact on quality of life2, and result in hospitalisation5-9, thereby putting pressure on local healthcare systems. Coloplast is now launching Luja, the first and only male catheter featuring 80+ micro-holes, aiming to address important UTI risk factors1 linked to intermittent catheterisation. Flow stops and blockage of the catheter eyelets during emptying increase the risk of leaving residual urine behind in the bladder. Residual urine increases the risk of bacteria growth and is a well-known UTI risk factor. The launch of Luja begins this month, February, in Denmark and Finland, and the product is expected to be available across Coloplast’s key markets over the next 12 months. Coloplast is currently conducting two pivotal clinical studies to document and demonstrate the benefits of Luja. The results are expected to be publicly available within the next few months. In 2021/22, the global market for continence care products was worth an estimated 15-16 billion DKK with an underlying annual market growth of 5-6%. Coloplast is the global market leader in continence care, and the company continues to outgrow the market and take market share. The launch of Luja is expected to contribute to Coloplast’s growth trajectory and help solidify the company’s global market leader position. Luja has close to no flow stops and complete bladder emptying is defined as <10 mL (CP353, NCT05485922). Announcement • Feb 03
Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23 Coloplast A/S provided earnings guidance for the Fiscal Year 2022/23. For the period, Organic revenue growth is expected at 7% to 8% in constant exchange rates. Reported EBIT margin before special items is still expected at 28% to 30%, impacted by increasing input costs, especially raw materials and electricity in Hungary, partly offset by leverage, efficiency gains and prudent management of operating costs. Upcoming Dividend • Nov 25
Upcoming dividend of kr.15.00 per share Eligible shareholders must have bought the stock before 02 December 2022. Payment date: 06 December 2022. Payout ratio is on the higher end at 90%, and the cash payout ratio is above 100%. Trailing yield: 2.3%. Lower than top quartile of German dividend payers (5.0%). Higher than average of industry peers (1.6%). Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Annette Bruls was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 09
Full year 2022 earnings released: EPS: kr.22.17 (vs kr.22.67 in FY 2021) Full year 2022 results: EPS: kr.22.17 (down from kr.22.67 in FY 2021). Revenue: kr.22.6b (up 16% from FY 2021). Net income: kr.4.71b (down 2.5% from FY 2021). Profit margin: 21% (down from 25% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 18
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr.5.85b (up 21% from 3Q 2021). Net income: kr.1.29b (up 2.8% from 3Q 2021). Profit margin: 22% (down from 26% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 12%, compared to a 7.6% growth forecast for the Medical Equipment industry in Germany. Reported Earnings • May 06
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: kr.5.50b (up 16% from 2Q 2021). Net income: kr.980.0m (down 13% from 2Q 2021). Profit margin: 18% (down from 24% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 14%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 10% per year. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Annette Bruls was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Jan 26
First quarter 2022 earnings: Revenues exceed analyst expectations First quarter 2022 results: Revenue: kr.5.17b (up 9.1% from 1Q 2021). Net income: kr.1.21b (up 6.3% from 1Q 2021). Profit margin: 23% (in line with 1Q 2021). Revenue exceeded analyst estimates by 1.9%. Over the next year, revenue is forecast to grow 10%, compared to a 13% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth. Executive Departure • Dec 03
Independent Director Birgitte Nielsen has left the company On the 2nd of December, Birgitte Nielsen's tenure as Independent Director ended after 6.0 years in the role. As of September 2021, Birgitte still personally held only 165.00 shares (€23k worth at the time). Birgitte is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 5.17 years. Upcoming Dividend • Nov 27
Upcoming dividend of kr.14.00 per share Eligible shareholders must have bought the stock before 03 December 2021. Payment date: 07 December 2021. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (3.3%). Higher than average of industry peers (0.9%). Reported Earnings • Nov 07
Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: kr.19.4b (up 4.8% from FY 2020). Net income: kr.4.83b (up 15% from FY 2020). Profit margin: 25% (up from 23% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 22
Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr.4.84b (up 9.4% from 3Q 2020). Net income: kr.1.25b (up 26% from 3Q 2020). Profit margin: 26% (up from 23% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 07
Second quarter 2021 earnings released The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: kr.4.75b (down 1.5% from 2Q 2020). Net income: kr.1.13b (up 5.9% from 2Q 2020). Profit margin: 24% (up from 22% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Mar 06
New 90-day low: €117 The company is down 1.0% from its price of €119 on 04 December 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €102 per share. Reported Earnings • Feb 03
First quarter 2021 earnings released The company reported a solid first quarter result with improved earnings, although revenues and profit margins were flat. First quarter 2021 results: Revenue: kr.4.74b (flat on 1Q 2020). Net income: kr.1.14b (up 4.0% from 1Q 2020). Profit margin: 24% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Feb 03
Revenue beats expectations Revenue exceeded analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 7.0%, compared to a 13% growth forecast for the Medical Equipment industry in Germany. Is New 90 Day High Low • Feb 03
New 90-day high: €136 The company is up 6.0% from its price of €128 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €97.31 per share. Is New 90 Day High Low • Jan 14
New 90-day low: €119 The company is down 11% from its price of €133 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €106 per share. Upcoming Dividend • Nov 27
Upcoming Dividend of kr.13.00 Per Share Will be paid on the 8th of December to those who are registered shareholders by the 4th of December. The trailing yield of 2.0% is below the top quartile of German dividend payers (3.7%), but it is higher than industry peers (1.3%). Is New 90 Day High Low • Nov 24
New 90-day low: €122 The company is down 14% from its price of €142 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €84.19 per share. Analyst Estimate Surprise Post Earnings • Nov 05
Revenue misses expectations Revenue missed analyst estimates by 0.4%. Over the next year, revenue is forecast to grow 6.7%, compared to a 11% growth forecast for the Medical Equipment industry in Germany. Is New 90 Day High Low • Oct 27
New 90-day low: €128 The company is down 12% from its price of €145 on 29 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €74.65 per share. Is New 90 Day High Low • Oct 06
New 90-day low: €130 The company is down 8.0% from its price of €142 on 08 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €74.01 per share. 
